Jacob Plieth

Jacob has 27 years’ experience of writing about healthcare, and joined ApexOnco in 2023 after 11 years’ reporting on biopharmaceuticals for Evaluate Vantage. Before that he spent five years as an equity research analyst at Edison Investment Research, and has also worked at Dow Jones/Wall Street Journal and Scrip, where he was news editor.

Jacob is a biochemist by training. He is a well-known presence on Biotech TV and Biotech Hangout, and has spoken about pharmaceuticals on the BBC World Service and News 24, as well as chairing industry discussions at various meetings.